Serina Therapeutics (SER) Other Non-Current Liabilities (2022 - 2025)

Serina Therapeutics has disclosed Other Non-Current Liabilities across 4 years of filings, most recently posting $3.5 million for Q2 2025.

• In Q2 2025, Other Non-Current Liabilities fell 73.54% year-over-year to $3.5 million; the TTM figure through Jun 2025 stood at $3.5 million (down 73.54% YoY), while the FY2024 annual figure was $3.6 million, changed N/A from the prior year.
• Other Non-Current Liabilities came in at $3.5 million for Q2 2025 at Serina Therapeutics, up from $2.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $24.1 million in Q1 2024 to a low of $180000.0 in Q4 2022.
• Average Other Non-Current Liabilities over 4 years is $5.3 million, with a median of $2.6 million recorded in 2025.
• Year-over-year, Other Non-Current Liabilities jumped 6839.19% in 2024 and tumbled 89.23% in 2025.
• Over 4 years, Other Non-Current Liabilities stood at $180000.0 in 2022, then soared by 92.78% to $347000.0 in 2023, then jumped by 932.28% to $3.6 million in 2024, then declined by 0.92% to $3.5 million in 2025.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $3.5 million in Q2 2025, $2.6 million in Q1 2025, and $3.6 million in Q4 2024.